Human NKp30/NCR3 Antibody Summary
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
Human NKp30 Antibody Induces IFN-gamma Secretion in NK‑92 Cells. Human NKp30 Monoclonal Antibody induces IFN-gamma secretion in the NK-92 human natural killer lymphoma cell line in a dose-dependent manner, as measured using the Human IFN-gamma DuoSet ELISA Kit (Catalog # DY285B). The ED50 for this effect is typically 1-3 µg/mL.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: NKp30/NCR3
NKp30, along with NKp44 and NKp46, constitute a group of receptors termed “Natural Cytotoxicity Receptors” (1). These receptors play a major role in triggering NK‑mediated killing of most tumor cells lines. NKp30 is a type I transmembrane protein having a single extracellular V-like immunoglobulin domain (2). A physical association with the ITAM-bearing accessory protein, CD3 zeta, occurs via a charged residue in the NKp30 transmembrane domain. Ligation of NKp30 with a specific antibody results in phosphorylation of CD3 zeta (3). NKp30 is expressed on both resting and activated NK cells of the CD56dim, CD16+ subset that account for more that 85% of NK cells found in peripheral blood and spleen (4). NKp30 is absent from the CD56bright, CD16- subset that constitutes the majority of NK cells in lymph node and tonsil, however, its expression is up-regulated in these cells upon IL-2 activation (4). Studies with neutralizing antibodies reveal that NKp30 is partially responsible for triggering lytic activity against several tumor cell types and that it is the main receptor responsible for NK‑mediated lysis of immature dendritic cells (2, 5). The ligand(s) recognized by NKp30 has not been described.
- Moretta, L. and A. Moretta (2004) EMBO J. 23:255.
- Pende, D. et al. (1999) J. Exp. Med. 190:1505.
- Augugliaro, R. et al. (2003) Eur. J. Immunol. 33:1235.
- Ferlazzo, G. et al. (2004) J. Immunol. 172:1455.
- Ferlazzo, G. et al. (2002) J. Exp. Med. 195:343.
Product Datasheets
Citations for Human NKp30/NCR3 Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
8
Citations: Showing 1 - 8
Filter your results:
Filter by:
-
Morphological profiling of human T and NK lymphocytes by high-content cell imaging
Authors: Y German, L Vulliard, A Kamnev, L Pfajfer, J Huemer, AK Mautner, A Rubio, A Kalinichen, K Boztug, A Ferrand, J Menche, L Dupré
Cell Reports, 2021-07-06;36(1):109318.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Nanoscale Dynamism of Actin Enables Secretory Function in Cytolytic Cells
Authors: AF Carisey, EM Mace, MB Saeed, DM Davis, JS Orange
Curr. Biol., 2018-02-01;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
NKp30 isoforms and NKp46 transcripts in metastatic melanoma patients: Unique NKp30 pattern in rare melanoma patients with favorable evolution
Authors: M Messaouden, G Fregni, D Enot, N Jacquelot, E Neves, N Germaud, HJ Garchon, W Boukouaci, R Tamouza, J Chanal, MF Avril, A Toubert, L Zitvogel, S Rusakiewic, A Caignard
Oncoimmunology, 2016-03-10;5(12):e1154251.
Species: Human
Sample Types: Whole Cells
Applications: Functional Assay -
NKP30-B7-H6 Interaction Aggravates Hepatocyte Damage through Up-Regulation of Interleukin-32 Expression in Hepatitis B Virus-Related Acute-On-Chronic Liver Failure.
Authors: Zou Y, Bao J, Pan X, Lu Y, Liao S, Wang X, Wang G, Lin D
PLoS ONE, 2015-08-04;10(8):e0134568.
Species: Human
Sample Types: Whole Cells
Applications: Functional Assay -
Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.
Authors: Ferrari de Andrade L, Ngiow S, Stannard K, Rusakiewicz S, Kalimutho M, Khanna K, Tey S, Takeda K, Zitvogel L, Martinet L, Smyth M
Cancer Res, 2014-10-28;74(24):7298-308.
Species: Human
Sample Types: Whole Cells
Applications: Functional Assay -
NKp44 receptor mediates interaction of the envelope glycoproteins from the West Nile and dengue viruses with NK cells.
Authors: Hershkovitz O, Rosental B, Rosenberg LA, Navarro-Sanchez ME, Jivov S, Zilka A, Gershoni-Yahalom O, Brient-Litzler E, Bedouelle H, Ho JW, Campbell KS, Rager-Zisman B, Despres P, Porgador A
J. Immunol., 2009-07-27;183(4):2610-21.
Species: Human
Sample Types: Whole Cells
Applications: Functional Assay -
Many NK cell receptors activate ERK2 and JNK1 to trigger microtubule organizing center and granule polarization and cytotoxicity.
Authors: Chen X, Trivedi PP, Ge B, Krzewski K, Strominger JL
Proc. Natl. Acad. Sci. U.S.A., 2007-03-29;104(15):6329-34.
Species: Human
Sample Types: Whole Cells
Applications: Western Blot -
A novel binding assay to assess specificity of monoclonal antibodies.
Authors: Warren HS, Warren</LastName><ForeNam HS</Initia, Bettadapura J
J. Immunol. Methods, 2005-08-15;305(1):33-8.
Species: Human
Sample Types: Complex Sample Type
Applications: Epitope Mapping
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human NKp30/NCR3 Antibody
Average Rating: 5 (Based on 1 Review)
Have you used Human NKp30/NCR3 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
Good antibody worked as mentioned in data sheet. Leads to activation of NK cells.
